this is temporary AND WAS DISCUSSED in the last CC at the 8:35 minute mark. I’ll paste link to recording for reference .. specifically noted this may occur temporarily… and is explained .. click on link provide your email etc then use the passcode provided below to be able to watch the recording … you can fast forward to the time to if only wanting to hear a snippet at a time
Listen to the CC at this time portion for explanation: 7:31 Auditor change / 8k item 4.01 discussed 813 OTC OTCQB discussed
Here’s some other key time stops to get clarity for frequently asked questions : 4:45 start time 6:20 begin investors Q&A 7:00 SEC discussed 7:31 Auditor change / 8k item 4.01 discussed 813 OTC OTCQB discussed 8:56 Farmatsevtik Armenia 13:40 QNTA Main GOALS & PLANS 17:35 paxlovid relapse unlike escozine symptoms did not return 18:35 PROVISIONAL PATENT now “ABLE TO SHARE PUBLICLY” escozine Covid 19 therapy “important goal” 20:22 CHART escozine therapy results EFFICACY charts 21:36 patient lung exray showing ASTOUNDING RESULTS from MONOTHERAPY escozine 22:54 Chief Scientific Officer Dr Matalka breaks down escozine (lots of very good information easy to follow slides - science of escozine explained very well *** worth listening / watching this portion, great visuals and easy to understand science of how Escozine works against Covid 26:36 *** [ “polarization of escozine significantly increased cox-2 inhibition in comparison with non polarized venom”] 31:38 slide shown Escozine BLOCKS omicron 32:50 “beauty of Escozine” 33:30 COVID registration PROCESS versus CANCER Registration process 35:05 delay in Dominican Republic studies explained (** worth noting, ANY medical trial is at the mercy of available subjects that fit in a specified sub group etc .. Covid rates WERE down … NOW going back UP ) 36:37 currently Mexico has ENOUGH patients for DOUBLE BLIND study 37:13 Mexico EXPORT certificate (explains easier to import from US to Mexico .. double blind test mentioned again) 38:06 FDA strategy summarized “Actively working to completely FDA process” Funding discussed to finished indoor facility in DR 41:25 Dilution discussed ** last stage of closing with investors attorney to “avoid future dilution” *** 42:00 investor engaging with FDA LOBBYIST to help FDA process ** investor has experience w distribution of Covid 19 vaccines 42:43 FDA status - discussed “second potential investor” - help to move application from pre Ind to Ind status 43:08 a vision for DISTRIBUTION and New Opportunities 46:25 WALGREENS dialogue .. speaker has “experience in retail space for 30 years” … meeting with WALGREENS mentioned 49:28 Kevin Harrington (spelling??) Group REACHED out To QNTA expressing interest in Representing them - product samples to be shipped 50:00-51:54 *LICENSING discussed* (noted / reminder in the CC big pharma moves slow / process takes time) 51:56 name & SYMBOL CHANGE addressed 52:45 VENDING MACHINE lease discussed - modern style with visual screens for product video (ability to have video screen on the machine itself is what I understood) 53:57 Shared CEO position defined Activitie negotiations for CEO position, third round of interviews completed - CANDIDATE has extensive biotech experience & EXPERIENCE in taking Otc company to NASDAQ roles of co ceo positions discussed 55:50 addressed the PRE IND # and shows slide with direct communication with FDA showing the validity of the pre Ind # 56:45 dispels myth of his salary 57:25 “life’s work” *** worth hearing this portion, imo, shows a testimony and drive of the culmination research to where qnta is now and moving forward on a continued path in a achieving goals *** As always, one should do DD Listen to the CC. Read the data etc GLTA *** Cc link and code link below;
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.